On October 27, 2023, the Public Health Agency of Canada (PHAC) released the National Advisory Committee on Immunization’s (NACI) Updated guidance on the use of COVID-19 vaccines in individuals who have not previously been vaccinated against COVID-19. This guidance is based on current evidence and NACI expert opinion.
On September 12 and 28, 2023, Health Canada authorized XBB.1.5-containing mRNA COVID-19 vaccine products (Moderna Spikevax XBB.1.5 and Pfizer-BioNTech Comirnaty Omicron XBB.1.5 respectively) for use in individuals 6 months of age and older.
The updated COVID-19 vaccines have been authorized for those who have never previously received a COVID-19 vaccine (also referred to as a “primary series”) and those previously vaccinated with COVID-19 vaccines.
As a result of the evolving landscape in Canada, with a significant portion of the population having either received COVID-19 vaccinations or developed immunity through prior exposure to SARS-CoV-2, there is a need to adapt vaccination strategies and schedules to align with the changing circumstances.
- Recommendation
- Americas
- Canada
- COVID-19
